PCA 500-- the world's most efficient and versatile 12-lead ECG, just received FDA clearance for pediatric use
Retrieved on:
Tuesday, October 4, 2022
LQTS, Hospital, SIDS, Cardiology, Technology, ECG, CEO, EKG, Multimedia, NIH, Long QT syndrome, Digital, FDA, School, PCA, CRO, American Academy, Partnership, Child, Conference, Patient, Sudden death, We Play (EP), Medical device
LOS ANGELES, Oct. 4, 2022 /PRNewswire/ -- QT Medical announces FDA clearance of PCA 500, a resting 12-lead electrocardiogram (ECG or EKG), for use in pediatric patients.
Key Points:
- LOS ANGELES, Oct. 4, 2022 /PRNewswire/ -- QT Medical announces FDA clearance of PCA 500, a resting 12-lead electrocardiogram (ECG or EKG), for use in pediatric patients.
- The development of PCA 500's pre-positioned electrodes and compact recorder was initially funded by NIH for an easy-to-use ECG specifically designed for pediatric use.
- QT Medical will introduce PCA 500 to the pediatric market at the 2022 American Academy of Pediatrics National Conference.
- said Dr. Ruey-Kang Chang, CEO of QT Medical, Inc.
Two new initiatives will be announced at the pediatric market launch of PCA 500.